Preoperative oral celecoxib versus preoperative oral rofecoxib for pain relief after thyroid surgery

Basit Öğe Kaydı
dc.authoridColak, Alkin/0000-0001-9103-4844
dc.authorwosidColak, Alkin/R-8739-2017
dc.contributor.authorKaramanlioglu, B
dc.contributor.authorArar, C
dc.contributor.authorAlagöl, A
dc.contributor.authorÇolak, A
dc.contributor.authorGemlik, I
dc.contributor.authorSüt, N
dc.date.accessioned2024-06-12T10:51:35Z
dc.date.available2024-06-12T10:51:35Z
dc.date.issued2003
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground and objective: The study compared the analgesic efficacy and safety of two preoperatively administered cyclo-oxygenase-2 inhibitors, celecoxib and rofecoxib. Methods: Ninety adult patients undergoing thyroid surgery were divided into three groups (each n = 30). They were given a single oral dose of placebo, celecoxib 200 mg or rofecoxib 5 0 mg 1 h before induction of anaesthesia. All patients received a standard anaesthetic. Intraoperative blood loss was measured. Pain scores, sedation scores, heart rate, mean arterial pressure and respiratory rate were noted at 0, 1, 2, 4, 6, 12 and 24 h postoperatively. Analgesic (meperidine) requirements and adverse effects were recorded during the first postoperative 24 h. Results: Compared with placebo, pain scores were significantly lower with rofecoxib at all time points (P < 0.05) and were significantly lower with celecoxib (P < 0.05) during the first 4 h. Pain scores were significantly lower with rofecoxib compared with celecoxib at 6, 12 and 24 h (P < 0.05). The average cumulative 24 h meperidine dose was significantly lower with both celecoxib (54.9 +/- 34.4 mg) and rofecoxib (42.8 +/- 40.9 mg) compared with placebo (76.8 +/- 6.2 mg) (P < 0.01 and P < 0.001, respectively). There were no differences in the intraoperative blood loss, heart rate, mean arterial pressure, respiratory rate, sedation scores and incidence of adverse effects among groups. Conclusions: The preoperative administration of rofecoxib 50 mg and less so of celecoxib 200 mg provide a significant analgesic benefit with regard to postoperative pain relief and decrease in additional opioid requirements after thyroid surgery.en_US
dc.identifier.doi10.1097/00003643-200306000-00013
dc.identifier.endpage495en_US
dc.identifier.issn0265-0215
dc.identifier.issn1365-2346
dc.identifier.issue6en_US
dc.identifier.pmid12803270en_US
dc.identifier.scopus2-s2.0-0038101659en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage490en_US
dc.identifier.urihttps://doi.org/10.1097/00003643-200306000-00013
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18404
dc.identifier.volume20en_US
dc.identifier.wosWOS:000183501700013en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofEuropean Journal Of Anaesthesiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectANALGESIC TECHNIQUES, Preoperativeen_US
dc.subjectANALGESICS, NON-OPIOID, Celecoxiben_US
dc.subjectParacetamol, Rofecoxiben_US
dc.subjectANALGESICS, OPIOID, Meperidineen_US
dc.subjectPAIN, Postoperativeen_US
dc.subjectSURGERY, Thyroiden_US
dc.subjectDental Painen_US
dc.subjectMorphine Consumptionen_US
dc.subjectAnalgesic Efficacyen_US
dc.subjectCyclooxygenase-2en_US
dc.subjectInhibitoren_US
dc.subjectCox-2en_US
dc.subjectDiclofenacen_US
dc.subjectNaproxenen_US
dc.titlePreoperative oral celecoxib versus preoperative oral rofecoxib for pain relief after thyroid surgeryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu